Shanghai Kaibao Pharmaceutical Co., Ltd.
上海凯宝
300039
Shenzhen Stock Exchange
Company Profile
The company has built a high-tech platform with strong R&D and production capability transformation, and also Shanghai academician expert workstation with many research projects. At present, At present, the main product has a definite clinical curative effect and stable quality, and the market coverage rate and enterprise recognition are gradually improved lead to a gradually improved market fraction of coverage and enterprise recognition. Jointly cooperation with Shanghai Institute and Chongqing University study 689 material basic research and improve the quality standard to reach a result 8893 which lay a solid foundation to ensure the product quality. In collaboration with China Medicine University work out the research of pharmacokinetics to provide a scientific basis for clinical use. Finished the national administration of traditional Chinese medicine project 30 thousand cases safety evaluation through real world safety analysis. Working with China Song Ching Ling foundation to carry out the 10 thousand cases of reevaluation about project effectiveness on the research of senile chronic obstructive pulmonary disease. Undertake the National Development and Reform Commission project of the standardization construction of Tanreqing Injection to build the product into an exemplary brand of the industry. Cooperate with China Academy of Chinese Academy of Sciences in the study of drug-resistant to make positive contributions to solve the world drug resistance problem. Company focuses on sales team building and marketing mode improvement to insist on academic promotion also think highly of terminal market maintenance and development to improve the market share and brand competitiveness.
Full description
The company is a comprehensive pharmaceutical enterprise mainly engaged in research, development, manufacture and sale of modern Chinese medicine. Which is a national modern high-tech industrialization demonstration project base of Chinese medicine and one of the top 100 pharmaceutical enterprises in China. It is the first batch of Chinese medicines approved by the new GMP (2010 edition) injections companies. The main production Tanreqing injection is a exclusive patented product belongs to national second-class new traditional Chinese medicine. Because of the advanced process engineering, excellent quality and extremely safety, it has very clear clinical advantages which are significant curative effect, lower side-effect and it is difficult to have drug resistance. In recent years Tanreqing is listed as a clinical guidelines medicine by the State Planning Commission and the State Administration of traditional Chinese medicine in "SARS" and "avian flu", "H1N1", "hand foot and mouth disease", "H7N9", "dengue fever" and other major epidemic. It is also listed as flu prevention medicine and national strategic reserve drugs by National Development and Reform Commission. Those achievements are the strong core competitiveness of this product. The company products team has been developed. For preclinical studies: in vitro cultivation of bear gall power which was included in the national "13th Five-Year" major drug discovery projects. It has made a major technical breakthrough in making kilograms level production. This is another equivalent alternative in rare Chinese herbal after bezoar and musk which has important significance in protecting endangered species of animals and the development of traditional Chinese medicine. II clinical products: Youxinding capsule which is the first clinical approval of national 1 class innovative medicines in mental field also included in "12th Five-Year" national major projects. III clinical products: with broad-spectrum antitumor activity of Paclitaxel injection, Dulanaming injection, Ding Guiyou soft capsule , Huadan liquid, Hydrophobic capsule and Tanreqing oral liquid. Shanghai Kaibao pharmaceutical Xinyi (Xinxiang) Co. Ltd as a wholly owned subsidiary is a high-tech enterprise mainly focusing on Chinese and Western medicine research, development, manufacture and sale. It has 148 approval numbers within 7 forms. Main products are exclusive product sidium Tiopronin for injection and Qishen capsules. In recent years, the market share of domestic liver diseases and cardiovascular and cerebrovascular diseases has increased rapidly. Shanghai kaibao fund investment and management Co. Ltd as a wholly owned subsidiary is a platform for industrial integration and expansion and exploring potential investment opportunities in biomedicine field also improving capital utilization efficiency, profitability and profitability to enhance the competitiveness of the company Shanghai kaibao Health Technology Co. Ltd as a wholly owned subsidiary is mainly focusing on technology development in the field of health science, product development of bear gall series and health counseling aiming to keep up with the rapid development of national pharmaceutical and healthcare industries.